Cumberland pharmaceuticals receives fda orphan drug and rare pediatric disease designations for new treatment of duchenne muscular dystrophy

Nashville, tenn. , nov. 6, 2024 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, announced today that the united states (u.s.) food and drug administration (fda) granted orphan drug designation and rare pediatric disease designation to ifetroban for the treatment of cardiomyopathy associated with duchenne muscular dystrophy (dmd).
CPIX Ratings Summary
CPIX Quant Ranking